Clinical Trial Update: Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB) [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing the GTX combination of gemcitabine, docetaxel, and capecitabine in metastatic pancreatic cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Taxotere (docetaxel)
• Xeloda (capecitabine)

Snippet

Sponsor: Columbia University | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-06-22